结节性硬化症耐药性癫痫切除手术的前瞻性全国多中心队列研究
该研究为前瞻性多中心队列,纳入中国21个中心2019至2022年适合切除手术的TSC相关DRE患者,手术组与药物组各100例,随访≥2年。倾向性评分匹配后,手术组1年无发作率为77%,药物组为13%;手术组IQ与生活质量改善更显著,安全性相当。
要点
- TSC相关DRE患者切除术后1年无发作率77%,显著高于药物组13%。
- 手术是减少癫痫复发的独立预测因素(HR 0.10,95%CI 0.05-0.17,p<0.0001)。
- MRI上的突出结节是术后无发作的独立预测因素,手术安全性可比药物。
核心结论
- 切除手术在TSC相关DRE患者中控制癫痫发作、改善IQ和生活质量方面显著优于药物,1年无发作率达77%,安全性相当。
研究设计与样本
- 前瞻性全国多中心队列研究,纳入中国21个中心2019至2022年适合切除手术的TSC相关DRE患者,手术组和药物组各100例,随访≥2年,采用倾向性评分匹配平衡基线特征。
主要发现
- 倾向性评分匹配调整后,手术组1、2、3、4年无发作率分别为77%、67%、66%、67%,药物组分别为13%、7%、6%、4%。
- 切除手术是减少入组后癫痫复发的最强独立预测因素(风险比0.10,95%CI 0.05-0.17,p<0.0001)。
- 术后2年随访时IQ和生活质量显著改善,且所有随访点抗癫痫药物使用减少(p<0.01)。
- MRI上的突出结节是术后低癫痫复发的独立因素,未发现严重并发症,不良事件无显著差异。
关键数值与推荐
- 手术组1年无发作率77%,药物组13%;2年分别为67%和7%。
- 手术减少癫痫复发的风险比0.10(95%CI 0.05-0.17,p<0.0001)。
- IQ和生活质量改善及抗癫痫药物减少的p值均<0.01。
临床怎么用
- 对于TSC相关DRE且适合切除手术的患者,切除手术可作为有效治疗选择,能显著提高无发作率并改善认知与生活质量。
- MRI显示突出结节的患者术后无发作可能性更高,术前评估应关注此特征。
局限性
- 存在选择偏倚,且可能存在中心(site)混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Resective surgery is an effective treatment for tuberous sclerosis complex (TSC)-related drug-resistant epilepsy (DRE). However, high-level evidence validating the effectiveness and safety of this technique is lacking. This study aimed to provide prospective multicenter data comparing resective surgery with medicine treatments. METHODS: This prospective cohort study included patients with TSC-related DRE who were suitable for resective surgery from 2019 to 2022 were identified from 21 centers in China. After collection, patients who underwent resective surgery were entered into the surgery group, whereas those who refused surgery and continued medicine treatment were included in the medicine group. Follow-ups for ≥2 years tracked seizure control, IQ, quality of life (QOL), antiseizure medications (ASMs), and adverse events. Propensity score matching (PSM) was performed to balance baseline demographics and clinical characteristics. Seizure-freedom probabilities were estimated using Kaplan-Meier analysis, and the mixed effects Cox proportional hazards model assessed the risk of seizure recurrence alongside other covariates. RESULTS: Each group comprised 100 patients with a total median age of 6.70 years (interquartile range, 3.73-12.80), and 35% were female patients. PSM-adjusted seizure-freedom rates in the surgery group were 77%, 67%, 66%, and 67% at 1-, 2-, 3-, and 4-year follow-ups, respectively, compared with 13%, 7%, 6%, and 4% in the medicine group. The surgery group had a higher probability of achieving seizure freedom. Resective surgery was identified as the strongest independent predictor reducing post-collection seizure recurrence (hazard ratio, 0.10; 95% CI, 0.05-0.17; p < 0.0001). Significant improvements in IQ and QOL were found at the 2-year follow-up, along with reductions in ASMs across all follow-ups after surgery (p < 0.01). Outstanding tubers were the independent factor for postoperative low seizure recurrence. Serious complications were not found, and no significant differences in adverse events were observed. DISCUSSION: Resective surgery demonstrates significantly higher effectiveness than medicine in seizure control and improvements of IQ and QOL in patients with TSC-related DRE, achieving a 1-year seizure-freedom rate of 77%. Furthermore, the safety of resective surgery is comparable with that of medicine. Outstanding tubers on MRI is an independent predictor of postoperative seizure freedom. Selection bias and possible confounding by site are limitations of this study. TRIAL REGISTRATION INFORMATION: Registered with ClinicalTrials.gov as TRE-RES. Registration number: NCT04198181. Date of the registration submitted to the registry: November 10, 2019. Date of first patient enrollment: December 12, 2019. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that resective surgery provides better seizure control, and improved IQ and quality of life, than medication alone in patients with TSC.
引用
- Wei Z, Liu T, Cao D, et al. Resective Surgery for Drug-Resistant Epilepsy in Patients With Tuberous Sclerosis Complex: A Prospective Nationwide Multicenter Cohort Study. Neurology. 2025. PMID: 41100778. doi:10.1212/WNL.0000000000214260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。